Life Attenuated Vaccines Market, By Product Type (Bacterial and Viral), By Technology (Classical Techniques, Live Attenuation, Inactivated/Killed, Advanced Techniques, Recombinant DNA Technology, and Viral Vector Technology), By Indication (Tuberculosis, Measles, Rotavirus, Yellow Fever, Oral Polio, and Others), By Mode of Administration (Injectable, Intranasal, Oral, and Others), By Age Group (Pediatric Vaccines, Adult Vaccines, and Geriatric Vaccines), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Mar 2025

Code : CMI7758

Pages :160

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Concentration and Competitive Landscape

Life Attenuated Vaccines Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Key Developments:

In November 2023, the U.S. FDA approved Ixchiq, the first live attenuated vaccine for Chikungunya, via accelerated approval. While it marks a significant step in combating the virus, key considerations include planned studies to address safety and efficacy concerns. Notably, 1.6% of recipients experienced severe chikungunya-like adverse reactions affecting daily activity or requiring medical intervention.
In November 2023, Valneva SE, a specialty vaccine company, announced the U.S. FDA approval of IXCHIQ, a single-dose, live-attenuated vaccine for preventing chikungunya virus (CHIKV) in adults 18+ at increased risk. The approval, granted under accelerated review based on antibody response, requires confirmation of clinical benefits in ongoing studies.
In December 2022, Takeda Pharmaceutical Company, a biopharmaceutical company, announced that the European Commission approved QDENGA (Dengue Tetravalent Vaccine [Live, attenuated]) for preventing dengue in individuals aged 4+ in the EU. This approval follows a positive CHMP recommendation in October 2022 and aims to reduce the global dengue burden, offering a preventive tool for residents and travelers to dengue-endemic regions.

Top Strategies Followed by Global Life Attenuated Vaccines Market Players

Established Players: Leading companies prioritize extensive research and development to innovate high-performance vaccines
- For instance, in May 2024, BioNTech SE received US$ 145 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to expand its manufacturing facility in Kigali, Rwanda, enhancing mRNA vaccine production capabilities
Mid-Level Players: Mid-sized companies in the market strive to deliver quality and affordable vaccine products targeting price-sensitive customers. They focus on developing cost-effective solutions without compromising on safety and efficacy.
- For example, in March 2024, Bharat Biotech, a biotechnology company, in partnership with a Spain-based biopharma firm, Biofabri, initiated Phase 3 clinical trials for MTBVAC, the first live attenuated TB vaccine derived from a human strain
Small-Scale Players: Startups like Vaxart are developing advanced technologies, including oral vaccine delivery systems that enhance patient compliance. Their innovative approach is expected to significantly influence market dynamics by providing easier administration methods.

Emerging Startups - Life Attenuated Vaccines Industry Ecosystem

Innovative Technologies: Vaxess Technologies is pioneering the MIMIX sustained dermal delivery platform, which combines high-temperature stability with improved efficacy, facilitating vaccine access in regions lacking reliable cold chain infrastructure. The development of heat-stable vaccines by startups like Vaxess is poised to revolutionize vaccine distribution, particularly in low-resource settings where maintaining cold chains is challenging.
Sustainable Solutions: A few startups emphasize sustainability. For example, Anthropic develops AI safety techniques to facilitate effective yet eco-friendly vaccine production. Compass Biotech employs hydrogen fuel cell technology and renewable energy sources in its facilities to manufacture vaccines with a smaller carbon footprint.

Key Players Insights